OptiBiotix Health
OPTI · AIM · Health Care · mcap £6.1m · 5.9p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 17 Sep 26 | Results | Half-year Results
H1 2026 revenues up 21.9% to £679k with improving margins and cost reductions; Rest of World sales up 133%. |
−9.8% |
| 15 Sep 26 | OptiBiotix Ltd Directorate Changes
Imad Farhat appointed as non-executive director of OptiBiotix Ltd subsidiary. |
+1.6% | |
| 08 Sep 26 | SweetBiotix® Update
OptiBiotix reports progress on SweetBiotix product development with enzyme breakthrough and interest from major beverage companies. |
+0.0% | |
| 02 Sep 26 | H&B launches FORMI™ Product containing SlimBiome®
Holland & Barrett launches FORMI Weight Loss Complex containing OptiBiotix's SlimBiome formulation in 1,600 stores worldwide. |
+1.8% | |
| 26 Jun 26 | Investor presentation and Q&A
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces tha |
+0.0% | |
| 02 Jun 26 | Investor presentation and SweetBiotix® Sampling
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces tha |
+0.0% | |
| 28 May 26 | Final Results & Notice of AGM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute announces its audited result |
+6.1% | |
| 14 May 26 | SweetBiotix® Sampling
OptiBiotix to hold shareholder event in June 2026 to demonstrate SweetBiotix products |
+14.0% | |
| 01 May 26 | Partial Disposal of Shares in SkinBioTherapeutics
OptiBiotix sold 7.5m shares in SkinBioTherapeutics for £675,000, retaining 2.2% stake. |
+4.1% | |
| 01 Apr 26 | Trading update | Trading Update
Revenue up 30% to £1.13m, gross profit up 82% to £603k, with record orders and cost reduction plan. |
+6.1% |
| 24 Feb 26 | WellBiome® clinical trial on surgical outcomes
OptiBiotix commences clinical trial of WellBiome with Hull University Teaching Hospital NHS Trust on cardiac surgery outcomes. |
+1.6% | |
| 17 Feb 26 | Statement: SkinBioTherapeutics Announcement
OptiBiotix clarifies it holds 5.64% of SBTX, will not sell, and reports £1m cash at year-end with 2026 orders over £800k. |
+8.5% | |
| 21 Jan 26 | Large Order and Record Early Orders for 2026
OptiBiotix receives four orders totalling 24 metric tonnes of SlimBiome from Taiwan distributor Meelung and secures record £800k early orders for 2026. |
+18.7% | |
| 20 Jan 26 | New Investor Website
OptiBiotix launches new interactive investor website for shareholder engagement and information access. |
+0.0% | |
| 24 Nov 25 | SweetBiotix Overview and Update
OptiBiotix updates on SweetBiotix product development, announces new high-yield enzyme process and manufacturing improvements. |
−2.5% | |
| 17 Nov 25 | Order with well-known Weight Management Company
First order received from weight management company for private label SlimBiome and WellBiome products, delivery planned H1 2026. |
+6.5% |
Company filings. Not investment advice.